PMID

Data

Article Title

Organization

Continued optimization of the M

Vanderbilt University School of Medicine

Challenges in the development of an M

Vanderbilt University Medical Center

Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.

Vanderbilt University Medical Center

Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380).

Vanderbilt University Medical Center

Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).

Vanderbilt University

Discovery of ML326: The first sub-micromolar, selective M5 PAM.

Vanderbilt University Medical Center

Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists.

University of Arkansas For Medical Sciences

Further exploration of M1 allosteric agonists: subtle structural changes abolish M1 allosteric agonism and result in pan-mAChR orthosteric antagonism.

Vanderbilt University Medical Center

Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia.

Vanderbilt University Medical Center

Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists.

Vanderbilt Institute of Chemical Biology

Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.

Vanderbilt University Medical Center

An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission.

Dvanderbilt Program In Drug Discovery

Discovery of a potent M

Vanderbilt University

Development of

Vanderbilt University

Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M

Vanderbilt University Medical Center

VU6005806/AZN-00016130, an advanced M

Vanderbilt University School of Medicine

cis-1,3,4,6,7,11b-Hexahydro-2-methyl-7-phenyl-2H-pyrazino[2,1-a] isoquinoline: a new atypical antidepressant.

TBA

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand.

University of Shizuoka

Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists.

Vanderbilt University School of Medicine

Optimization of M

Vanderbilt University Medical Center